Patents Represented by Attorney Wilson Sonsini Goodrich & Rosati
  • Patent number: 8350070
    Abstract: Simple, economical preparative processes for the provision of pure hydroxyl functional materials that are derived by converting the alkene groups of the unsaturated molecules found in vegetable oils, into hydroxyl groups.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: January 8, 2013
    Assignee: Biobased Technologies LLC
    Inventors: David M. Casper, Trevor Newbold
  • Patent number: 8348665
    Abstract: An activatable dental appliance. A concave trough conforms to a plurality of teeth when placed over the plurality of teeth. A first force applying region is configured to apply a first force to at least one tooth of the plurality of teeth for repositioning the tooth. A second force applying region is configured to be selectively activated, wherein when selectively activated the second force applying region applies a force to at least one tooth of the plurality of teeth.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: January 8, 2013
    Assignee: Align Technology, Inc.
    Inventor: Eric Kuo
  • Patent number: 8349353
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with cytotoxic agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: January 8, 2013
    Assignees: Otonomy, Inc., The Regents of the University of California
    Inventors: Jay Lichter, Andrew M. Trammel, Jeffrey P. Harris, Carl Lebel, Fabrice Piu, Qiang Ye, Luis A. Dellamary
  • Patent number: 8349554
    Abstract: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: January 8, 2013
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: S. Bahram Bahrami, Mandana Veiseh, James Olson
  • Patent number: 8342182
    Abstract: Lung conditions are diagnosed and optionally treated using a functional assessment catheter or a functional lung assessment and treatment catheter. A flow restrictive component is initially placed in a bronchus or lung passageway upstream from a diseased lung region. The isolated lung region is then functionally assessed through the catheter, while the flow restrictive component remains in place. If the patient is a good candidate for treatment by occlusive or restrictive treatment techniques, the flow resistive component may be left in place. If the patient is not suitable for such treatment, the flow resistive component may be removed.
    Type: Grant
    Filed: August 27, 2007
    Date of Patent: January 1, 2013
    Assignee: Pulmonx Corporation
    Inventors: Ajit Nair, Son Gia, Roger Farhnoltz, Nikolai Aljuri
  • Patent number: 8344012
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: January 1, 2013
    Assignee: Ardea Biosciences, Inc.
    Inventors: Esmir Gunic, Jean-Luc Girardet, David A. Paisner
  • Patent number: 8346365
    Abstract: Methods and apparatus for improving cognitive function within a human. The invention utilizes an implanted device, such as an implantable signal generator or an implantable pump, to affect tissue elements within a Papez circuit of the human brain as well as tissue upstream or downstream from the Papez circuit. The implanted device delivers treatment therapy to thereby improve cognitive function by the human. A sensor may be used to detect various symptoms of the cognitive disorder. A microprocessor algorithm may then analyze the output from the sensor to regulate delivery of the stimulation and/or drug therapy.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: January 1, 2013
    Assignee: Functional Neuromodulation, Inc.
    Inventor: Andres M. Lozano
  • Patent number: 8343078
    Abstract: Methods, systems and devices for evaluating the integrity of a uterine cavity. A method comprises introducing transcervically a probe into a patient's uterine cavity, providing a flow of a fluid (e.g., CO2) through the probe into the uterine cavity and monitoring the rate of the flow to characterize the uterine cavity as perforated or non-perforated based on a change in the flow rate. If the flow rate drops to zero or close to zero, this indicates that the uterine cavity is intact and not perforated. If the flow rate does not drop to zero or close to zero, this indicates that a fluid flow is leaking through a perforation in the uterine cavity into the uterine cavity or escaping around an occlusion balloon that occludes the cervical canal.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: January 1, 2013
    Assignee: Minerva Surgical, Inc.
    Inventor: Akos Toth
  • Patent number: 8337993
    Abstract: Wallboards, as well as other building materials, are produced by methods which use significantly reduced embodied energy, generating far less greenhouse gases when compared with the energy used to fabricate gypsum wallboard. A novel cementitious core, consisting in one embodiment of post-industrial waste such as slag and combined with pH modifiers, provides a controlled exothermic reaction to create a gypsum-wallboard-like core which can be wrapped in a selected material such as recycled paper and manufactured on a conveyor system to appear, weigh and handle similar to gypsum wallboard, but without the large amounts of energy required to make gypsum wallboard. The manufacturing process results in lower greenhouse gas emissions than the processes used to make gypsum wallboard.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: December 25, 2012
    Assignee: Serious Energy, Inc.
    Inventors: Kevin Surace, Meredith Ware, Denise Hoover, Jiaping Han, Tiandan Chen
  • Patent number: 8338416
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: December 25, 2012
    Assignee: Pharmacylics, Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
  • Patent number: 8338387
    Abstract: Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: December 25, 2012
    Assignee: California Institute of Technology
    Inventors: Linda C. Hsieh-Wilson, Sarah E. Tully, Ross Mabon, Cristal I. Gama
  • Patent number: 8338485
    Abstract: The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 8338164
    Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: December 25, 2012
    Assignee: The Foundry, LLC
    Inventors: Mark E. Deem, Hanson Gifford
  • Patent number: 8338486
    Abstract: The invention provides methods for administering extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form of memantine achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: December 25, 2012
    Assignee: Adamas Pharmaceuticals, Inc.
    Inventors: Gregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
  • Patent number: 8337589
    Abstract: A method and apparatus for extracting CO2 from air comprising an anion exchange material formed in a matrix exposed to a flow of the air, and for delivering that extracted CO2 to controlled environments. The present invention contemplates the extraction of CO2 from air using conventional extraction methods or by using one of the extraction methods disclosed; e.g., humidity swing or electro dialysis. The present invention also provides delivery of the CO2 to greenhouses where increased levels of CO2 will improve conditions for growth. Alternatively, the CO2 is fed to an algae culture.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: December 25, 2012
    Assignee: Kilimanjaro Energy, Inc.
    Inventors: Allen B. Wright, Klaus S. Lackner, Ursula Ginster
  • Patent number: 8337817
    Abstract: Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties; and a physiologically active substance.
    Type: Grant
    Filed: December 25, 2007
    Date of Patent: December 25, 2012
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventors: Ryoichi Nagata, Shunji Haruta
  • Patent number: 8338484
    Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: December 25, 2012
    Assignee: Panmira Pharmaceuticals, LLC
    Inventors: John Howard Hutchinson, Brian Andrew Stearns, Yen Pham Truong
  • Patent number: 8336712
    Abstract: Provided are systems, devices, dispensers, clips, and methods of using the same, for dispensing bandages comprising: a dispenser body defining an interior compartment and comprising a front wall with an exposed upper edge; a bandage pack disposed in the interior compartment; and a removable retaining clip adapted to reversibly interlock with the exposed upper edge of the front wall to retain a bandage pack in the dispenser body.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: December 25, 2012
    Inventor: Michael Holstein
  • Patent number: 8333796
    Abstract: Embolic coil implant systems and methods whereby coils are mechanically detachable are disclosed. The coils include a retention element that may be releasably retained within the distal end of an implant tool. The implant tool may include a fulcrum configured to engage a first filament and prevent the release of the coil when the first filament is engaged. Alternatively, an urging means and aperture may be disposed within the sidewall of the implant tool, and a first filament may, in conjunction with the aperture and sidewall, releasably retain the coil until the first filament is withdrawn. The implant tool may also include an alignment member for aligning the first filament.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: December 18, 2012
    Assignee: Penumbra, Inc.
    Inventors: Ben Tompkins, Arani Bose, Delilah Hui, David Barry, Stephen Pons, Aleksander Leynov
  • Patent number: 8334116
    Abstract: The present invention provides novel isothermal methods of generating multiple copies of, detecting and/or quantifying nucleic acid sequences of interest based on limited primer extension or attachment of oligonucleotide pairs using composite RNA/DNA primers. Methods for generating multiple copies of and/or detecting and/or quantifying nucleic acid sequences, wherein products of primer extension or attachment of oligonucleotide pairs comprising a cleavable portion are generated, and wherein cleavage of the products results in dissociation of cleaved products from target polynucleotides, are provided. The invention further provides compositions, kits and systems for practicing these methods.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: December 18, 2012
    Assignee: Nugen Technologies, Inc.
    Inventor: Nurith Kurn